Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
ABT-199 (Venetoclax) in Apoptosis Research
2026-09-16
ABT-199, also called Venetoclax, gives researchers a selective way to test BCL-2 dependence in hematologic cancer models and exploratory microglial systems. This guide connects quantitative apoptosis workflows with spatial findings from aged mouse white matter while clearly separating established use cases from cross-domain hypotheses.
-
Recombinant Mouse CD4, Tag Free: Research Guide
2026-09-15
Recombinant Mouse CD4, Tag Free (P2012) is best treated as an immunology research reagent for assay development, not as a validated colorectal cancer mechanism probe. The cited ZNF263–STAT3 study supports a CRC signaling model, but it does not establish that recombinant CD4 modulates that pathway.
-
Resiniferatoxin: Designing Better TRPV1 Assays
2026-09-15
Resiniferatoxin (RTX) is an ultra-potent TRPV1 agonist whose effects depend on exposure kinetics, neuronal phenotype, and membrane cholesterol context. This guide translates recent cyclodextrin findings into practical decisions for pain, calcium-imaging, and desensitization assays.
-
In Vitro Drug Response: Viability Versus Cell Death
2026-09-14
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing why growth suppression and actual cell killing should not be treated as interchangeable drug-response outcomes. Its time-aware, orthogonal framework offers a practical basis for interpreting apoptosis-focused studies and improving the translational value of in vitro cancer assays.
-
Proteinase K as a Protease Assay Control
2026-09-14
Proteinase K is more than a DNA digestion reagent: it can serve as a broad-spectrum serine protease comparator when interpreting inhibitor selectivity. This article connects recombinant enzyme behavior, DNA workflow design, and the SARS-CoV-2 3CLpro study to develop a practical assay decision framework.
-
Cisapride (R 51619) in iPSC Cardiotoxicity Screens
2026-09-13
Cisapride (R 51619) provides a mechanistically informative challenge compound for linking 5-HT4 receptor signaling with hERG channel inhibition in human cardiac models. This guide translates high-content iPSC-cardiomyocyte screening into practical dosing, imaging, electrophysiology, and troubleshooting workflows for cardiac arrhythmia research.
-
Measuring Cancer Drug Response Beyond Viability
2026-09-12
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of anticancer drug response. This framework supports more informative in vitro experiments by combining endpoint interpretation with attention to response magnitude, composition, and timing.
-
FGF Signalling and Non-Cell-Autonomous Apoptosis Resistance
2026-09-12
The reference study shows that apoptotic stress can make neighboring cells harder to kill: stressed cells release FGF2, which activates MEK–ERK signaling and increases pro-survival BCL-2-family proteins. This finding connects treatment-associated resistance in cancer biology with tissue repair and suggests that apoptosis assays should distinguish cell-intrinsic death from paracrine survival effects.
-
CAF–ANGPTL4–IQGAP1 Axis in Prostate Cancer
2026-09-11
The reference study identifies a paracrine ANGPTL4–IQGAP1 signaling axis through which cancer-associated fibroblasts enhance mitochondrial biogenesis, oxidative phosphorylation, and chemotherapy resistance in prostate cancer cells. Its combination of secretome proteomics, metabolic profiling, interaction assays, and drug screening nominates QGGP as a candidate strategy for improving docetaxel responsiveness, while also highlighting the importance of rigorous native-protein workflows.
-
JZL184 for MAGL and Endocannabinoid Research
2026-09-11
JZL184 is a selective monoacylglycerol lipase inhibitor for dissecting 2-arachidonoylglycerol control of synaptic, pain, and affective pathways. This practical guide connects target engagement, neuronal assays, LC-MS/MS, and behavioral endpoints while showing how to interpret findings alongside recent cannabidiol research.
-
H 89 2HCl for cAMP/PKA Signaling Assays
2026-09-10
H 89 2HCl enables practical interrogation of PKA-dependent phosphorylation, neurite remodeling, and cAMP-responsive signaling in biochemical and cell-based models. This guide combines concentration-aware workflow design with safeguards against vehicle effects and higher-dose inhibition of non-PKA kinases.
-
OSMI-1: O-GlcNAc Transferase Inhibitor
2026-09-10
OSMI-1 is a cell-permeable O-GlcNAc transferase inhibitor that reduces protein O-GlcNAcylation and produces a reported IC50 of 2.7 μM. Its cellular and zebrafish benchmarks support controlled O-GlcNAcylation research while also requiring explicit cytotoxicity and acute-toxicity controls.
-
Biotin-XX Tyramide Reagent for Surface Proteomics
2026-09-09
Biotin-XX Tyramide Reagent combines HRP-driven signal amplification with membrane-impermeant cell-surface labeling, making it useful for low-abundance targets in tissue imaging and proximity proteomics. Its long polar linker helps distinguish extracellular labeling from intracellular signal, supporting more selective astrocyte–neuron interface studies.
-
JSH-23: Mapping NF-κB Control in Macrophages
2026-09-09
JSH-23 is an NF-κB inhibitor designed to separate p65-dependent transcription from upstream pathway activation. This article presents a practical, mechanistic framework for using it in macrophage assays, inflammasome studies, and the cisplatin-induced acute kidney injury model.
-
Mc-Val-Cit-PABC-PNP ADC Linker Workflow
2026-09-08
Mc-Val-Cit-PABC-PNP is a cathepsin cleavable ADC peptide linker for research workflows involving lysosomal payload release during antibody-drug conjugate synthesis. It is highly soluble in DMSO but insoluble in water and ethanol, so it should be handled as a freshly prepared research reagent rather than an aqueous, diagnostic, or medical formulation.